MedPharm enjoys an enviable level of repeat business
We engaged MedPharm in one of our charter programs and have been thoroughly impressed with their level of technical expertise and team interactions. They have been a superb business partner, consistently demonstrating strong team leadership, providing proactive and reliable communications, finding creative approaches to meet out formulation goals, all while progressing the project forward without delays to the timeline. Their integrated team approach established the foundation for a strong partnership.
I have always found MedPharm’s service for the development of topical products first class. They provide a comprehensive package of data you know regulators trust and during any project advise on the best routes to approval based on their extensive knowledge and experience. The MedPharm team are always responsive and are particularly adept at finding creative solutions to more difficult formulation issues. Whenever I use them I know they are the best route for protecting our development investment.
We were lucky enough to start working with MedPharm back when we established an early virtual dermatology development company, Vicept Inc. We have subsequently worked with them on many projects because they have consistently maintained their position at being at the forefront of topical and transdermal drug delivery. This has been helped by them opening up their new laboratories in North Carolina. We greatly appreciate the insight their scientists provide on product as well as formulation design.
Cytovation has been working with MedPharm for a year and a half to develop our Cypep-1 to become the first real cure for treating warts. The development of a suitable cream to integrate the molecule has been a challenging work that the MedPharm team was able to solve. During the development process there have been numerous challenges that, in some cases, have been hard to overcome, but after some time solved in a way that made this possible to become a product approved for FIM. We have now received the clinical batch at site for starting our Phase I study, and I’d like to thank MedPharm for the effort it has shown for making this possible.